The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

A study measures the long-term downside of prostate cancer screening

A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
Byline
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account